Table 6 Subgroup analysis for predictors of treatment response in non-SARD patients (N = 71)
Factors | Unadjusted Odds Ratio (Univariate Analysis) | Adjusted Odds Ratio* (Multivariate Analysis) | ||
|---|---|---|---|---|
95% confidence interval | p-value | 95% confidence interval | p-value | |
Baseline inflammatory marker level | ||||
ESR status (Cut-off level: High vs. Low-normal) | ||||
• Total N = 43 | 1.64 (0.45–5.94) | 0.451 | 1.78 (0.46–6.95) | 0.404 |
• Exclude discordant case to CRP *N = 34 | 2.72 (0.62–12.04) | 0.187 | 3.48 (0.62–19.44) | 0.156 |
CRP status (Cut-off level: High vs. Low-normal) | ||||
• Total N = 61 | 3.50 (1.13–10.83) | 0.030 | 3.13 (0.97–10.05) | 0.056 |
• Exclude discordant case to ESR *N = 52 | 3.40 (0.996–11.602) | 0.051 | 3.45 (0.95–12.59) | 0.061 |
Age | 1.00 (0.956–1.051) | 0.917 | 1.01 (0.96–1.06) | 0.700 |
Gender | 0.93 (0.354–2.461) | 0.889 | 1.11 (0.40–3.06) | 0.844 |
Duration of anti-inflammatory treatment (at response evaluation) | 0.96 (0.885–1.043) | 0.343 | 0.96 (0.88–1.05) | 0.412 |
Antifibrotics in combination with anti-inflammatory treatment | 1.86 (0.42–8.18) | 0.410 | 1.45 (0.30–6.94) | 0.639 |
Baseline PFT | ||||
FVC (%predicted) *N = 71 | 0.98 (0.951–1.009) | 0.163 | 0.98 (0.95–1.01) | 0.167 |
DLCO (%predicted) *N = 64 | 0.99 (0.963–1.025) | 0.667 | 1.01 (0.97–1.05) | 0.565 |
Progression before initiate treatment | ||||
Meet any of the criteria | 1.13 (0.42–3.07) | 0.807 | 1.01 (0.35–2.88) | 0.989 |
PPF by ATS/ERS/JRS/ALAT 2022 | 0.23 (0.05–1.12) | 0.069 | 0.20 (0.04-1.00) | 0.050 |
PF-ILD by INBUILD criteria | 1.13 (0.41–3.07) | 0.807 | 1.01 (0.35–2.88) | 0.989 |
Baseline HRCT | ||||
• UIP pattern (typical & probable UIP) | 0.20 (0.04–1.09) | 0.063 | 0.12 (0.02–0.92) | 0.041 |
• Indeterminate UIP | 1.79 (0.24–13.54) | 0.572 | 2.39 (0.25–23.44) | 0.453 |
• fNSIP | 1 | - | 1 | - |